John Overdeck’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

John Overdeck’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,554	Closed	-$86K	–	2921
2022 Q2	$86K	Sell	3,554 -3,289	-48%	-$112K	﹤0.01%	2287
2022 Q1	$341K	Buy	6,843 +2,870	+72%	+$142K	﹤0.01%	2172
2021 Q4	$279K	Sell	3,973 -1,750	-31%	-$147K	﹤0.01%	3693
2021 Q3	$534K	Buy	+5,723	New	+$544K	﹤0.01%	3195
2020 Q4	–	Sell	-63,986	Closed	-$5.49M	–	3865
2020 Q3	$5.49M	Buy	63,986 +16,608	+35%	+$1.94M	0.02%	759
2020 Q2	$4.41M	Buy	+47,378	New	+$2.61M	0.02%	700
2019 Q4	–	Sell	-2,540	Closed	-$36K	–	4056
2019 Q3	$36K	Buy	+2,540	New	+$53.2K	﹤0.01%	3367
2019 Q2	–	Sell	-336	Closed	-$19K	–	3752
2019 Q1	$19K	Sell	336 -1,329	-80%	-$71.9K	﹤0.01%	2958
2018 Q4	$80K	Buy	1,665 +1,096	+193%	+$60.1K	﹤0.01%	2837
2018 Q3	$41K	Buy	+569	New	+$37.5K	﹤0.01%	3102
2018 Q1	–	Sell	-577	Closed	-$74K	–	3603
2017 Q4	$74K	Buy	+577	New	+$70.9K	﹤0.01%	3014

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

John Overdeck's VBIV Position: Q3 2022 in Review

John Overdeck sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2022, closing a stake of 3,554 shares — an estimated $86K sold.

John Overdeck first reported a position in VBIV in Q4 2017 and held it in 11 quarters. The position peaked at $5.49M in Q3 2020. 127 funds tracked by Wall St. Rank hold VBIV as of Q3 2022.

John Overdeck reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2022 after selling out during the quarter.
John Overdeck sold 3,554 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2022, an estimated $86K.
John Overdeck first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2017 and held it in 11 quarters.
John Overdeck's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $5.49M in Q3 2020.
127 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2022.

Based on Two Sigma Investments's 13F filing for Q3 2022, filed 14 Nov 2022.